Synthesis, Biological Evaluation and Ligand Based Pharmacophore Modeling of New Aromatic Thiosemicarbazones as Potential Anticancer Agents

Two series of new aromatic thiosemicarbazone derivatives were synthesized by condensation of N -(4-cyanophenyl)hydrazine carbothioamide ( I ) and N -(4-methylsulfanylphenyl)hydrazine carbothioamide ( II ) with appropriate aromatic aldehydes in order to investigate their antiviral and cytostatic pote...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical chemistry journal 2019-05, Vol.53 (2), p.139-149
Hauptverfasser: Karaküçük-İyidoğan, A., Aydınöz, B., Taşkın-Tok, T., Oruç-Emre, E. E., Balzarini, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Two series of new aromatic thiosemicarbazone derivatives were synthesized by condensation of N -(4-cyanophenyl)hydrazine carbothioamide ( I ) and N -(4-methylsulfanylphenyl)hydrazine carbothioamide ( II ) with appropriate aromatic aldehydes in order to investigate their antiviral and cytostatic potency. The chemical structures of all compounds were fully characterized by elemental analysis and spectroscopic techniques. The results of the bioassays indicated that compounds Id , Ie , If and IIf proved inhibitory against influenza virus A (EC 50 = 13 – 27 μg/mL for strain H1N1 and 9.3 – 18 μg/mL for strain H3N2). Compounds Ig and IIg were the most cytostatic compounds with inhibition of HeLa cell proliferation at an IC 50 = 0.3 μg/mL for Ig and 1.9 μg/mL for IIg . Especially, compound Ig showed the highest cytostatic activity with IC 50 of 0.30, 0.70 and 2.50 μg/mL against HeLa, CEM and L1210 cell lines, respectively. This inhibition range was within the same order of magnitude as that for cisplatin. Furthermore, molecular modeling was carried out to examine the cytostatic activity and determine the best pharmacophore model as a guide for the design and development of potential prodrugs in future studies.
ISSN:0091-150X
1573-9031
DOI:10.1007/s11094-019-01968-3